Azenta (NASDAQ:AZTA – Get Free Report) is scheduled to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Azenta to post earnings of $0.11 per share for the quarter. Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.16 earnings […]

ADC Therapeutics (NYSE:ADCT – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link. […]

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) will release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.45) per share for the quarter. Mirum Pharmaceuticals has set its FY 2024 guidance at EPS. Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly […]

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.52) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference […]

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Sangamo Therapeutics to post earnings of ($0.07) per share for the quarter. Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical […]

RealReal (NASDAQ:REAL – Free Report) had its price target increased by UBS Group from $3.00 to $3.25 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. REAL has been the subject of several other research reports. Robert W. Baird lowered their price target […]

Shares of WEX Inc. (NYSE:WEX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the thirteen analysts that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating […]

Landsea Homes (NASDAQ:LSEA – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at B. Riley in a report issued on Tuesday, Benzinga reports. They presently have a $18.00 price target on the stock, up from their prior price target of $17.00. B. Riley’s price objective would indicate a potential upside of […]

GlobalFoundries (NASDAQ:GFS – Get Free Report) had its target price decreased by equities research analysts at Citigroup from $45.00 to $40.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s target price suggests a potential downside of 3.31% from the […]

Shares of Coty Inc. (NYSE:COTY – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen analysts that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1-year price […]

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price target increased by Scotiabank from $62.00 to $70.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “sector outperform” rating on the stock. Scotiabank’s target price would indicate a potential upside of 8.07% from the stock’s previous close. IRON […]

ChromaDex (NASDAQ:CDXC – Free Report) had its price objective hoisted by HC Wainwright from $6.00 to $8.00 in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.06 EPS, Q1 […]

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in the […]

Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price target increased by HC Wainwright from $5.00 to $10.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month […]

Goosehead Insurance, Inc (NASDAQ:GSHD – Get Free Report) has earned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The […]

Shares of SM Energy (NYSE:SM – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy […]

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last […]

QUALCOMM (NASDAQ:QCOM – Free Report) had its target price cut by JPMorgan Chase & Co. from $210.00 to $195.00 in a research note published on Tuesday morning, Benzinga reports. They currently have an overweight rating on the wireless technology company’s stock. Several other equities analysts have also recently weighed in on QCOM. Rosenblatt Securities raised […]